Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia Active Not Recruiting Phase 2 Trials for Dasatinib (DB01254)

IndicationStatusPhase
DBCOND0114145 (Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00254423Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous LeukemiaTreatment